Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation.
Plote D, Choi W, Mokkapati S, Sundi D, Ferguson JE 3rd, Duplisea J, Parker NR, Yla-Herttuala S, Committee SCB, McConkey D, Schluns KS, Dinney CP.
Plote D, et al.
Oncoimmunology. 2019 Feb 20;8(5):e1577125. doi: 10.1080/2162402X.2019.1577125. eCollection 2019.
Oncoimmunology. 2019.
PMID: 31069136
Free PMC article.